Navigation Links
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Date:2/27/2008

r therapies.

Safety findings in the study were manageable and consistent with prior Phase II studies. Common adverse events in the study included mouth ulcers, high blood lipids, high blood sugar, skin rash, low red blood count, low phosphate levels, and inflammation of the lungs.

About Everolimus

Everolimus, an oral inhibitor of mTOR, is an investigational drug being studied in multiple tumor types. In cancer cells, everolimus inhibits mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism and blood vessel growth. Everolimus is a once-daily oral therapy that provides continuous inhibition of mTOR.

As an investigational compound, the safety and efficacy profile of everolimus has not yet been established in oncology. Access to everolimus is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will ever be commercially available for oncology indications anywhere in the world. Everolimus is approved under the trade-name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the EU in 2003 and is available in more than 60 countries.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "to be", "planned", "may", "offers", "potential", "could", "possibilities", "will", or similar expressions, or by express or implied discussions regarding potential future approvals for everolimus or regarding potential future revenues from everolimus. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with everolimus to be materially differen
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
5. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
6. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
7. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
10. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015 /CNW/ - T-Bird Pharma ... focused on developing premium quality medical marijuana products and ... Marihuana for Medical Purposes Regulations ( Canada ... with certain of its shareholders, has closed the transaction ... ("Medna").  Medna has acquired (the "Escrow Transfer") a total ...
(Date:4/24/2015)... -- Elekta has CE marked the latest version (v5.10) of ... European clinics to deliver a sophisticated radiation therapy planning ... planning, IMRT, VMAT and stereotactic planning – all in ... ® v5.10 provides significant planning and ... 3D planning as well as the addition of MRI ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3Elekta CE marks for Monaco v5.10 treatment planning system 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
... Knopp Neurosciences Inc. ("Knopp"),announced that the U.S. ... Development has granted orphan drug designation to ... (ALS). (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ) ... studies to evaluate the safety,tolerability and pharmacokinetics ...
... on stringent endpoint of clinical ... PHILADELPHIA, Oct. 15 An analysis of data to,be ... Scientific Meeting found that Asacol, dosed at 2.4 g/day, ... active,ulcerative colitis (UC). The analysis was based on data ...
Cached Medicine Technology:Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS 2New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 2New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 3New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 4
(Date:4/25/2015)... In the United States alone, an ... treatment for an illicit drug or alcohol ... Mental Health Services Administration’s Survey on Drug Use and ... are harrowing stories of men and women whose lives ... David H. Kerr , founder and retired president of ...
(Date:4/25/2015)... New York, NY (PRWEB) April 25, 2015 ... systems, technology and data for the enterprise relying on their ... and running smoothly. But according to an article ... CIOs can many times actually be doing a disservice to ... the i’s are dotted and t’s are crossed when it ...
(Date:4/25/2015)... Gardant Management Solutions will lead ... operations, and sales and marketing at the LeadingAge ... be held from April 29 through May 1 ... largest eldercare association in Illinois. The statewide association ... adults, including senior housing, assisted living and supportive ...
(Date:4/25/2015)... Sports controversies continue to revolve around issues of abuse and violence. ... the Miami Dolphins and Richie Incognito, or off the field and ... abuse case. In a recent episode of SCI TV , ... locker room culture on teams. He examines what worked for the ... improve the locker room as a work place. , Steele ...
(Date:4/24/2015)... 24, 2015 Bird B Gone, the leader ... now offers a complete line of bird control solutions to ... , New Flu Strains Threaten Pacific, Central and Mississippi Farms ... , a number of highly pathogenic avian flus in ... is often spread when wild birds enter poultry farms. The ...
Breaking Medicine News(10 mins):Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Gardant Management Solutions Staff Shares Operational Expertise 2Health News:David Steele Discusses Locker Room Culture on SCI TV 2Health News:David Steele Discusses Locker Room Culture on SCI TV 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4
... back, the 2008 Compensation Data results show benefits have seen little change ... ... October 29, 2008 -- General Motors has made headlines with plans to ... Retirees are also slated to loose health insurance coverage when they reach ...
... commercial with Jenny,Craig celebrity client, Valerie Bertinelli, ... pleased to,announce the three grand finalists of their ... Elaina Faustino and,Sara Hennessy are the three women ... TV commercial with Jenny Craig star client, Valerie ...
... (Nasdaq: WHRTD ) --,World Heart Corporation (WorldHeart or ... filing of articles of amendment with Industry,Canada under the ... Capital Market on a post-consolidation basis on October 28,2008. ... split at a Special Meeting of Shareholders held on ...
... Quarter Net Sales of $3.9 Million; 29% Increase ... - Second Fiscal Quarter U.S. Sales of $2.2 Million; 83% Increase ... Year-Over-Year -, - Multicenter Clinical Study Launched to Expand Reimbursement, Support ... Marketing - - Conference Call to be Held ...
... Oct. 29 Heralding the newest innovation,in home skin ... of light therapy, has announced the retail launch of ... Quasars are widely,acclaimed as the first professional devices made ... the Baby Quasar delivers exceptional,skin care results and can ...
... cloud symptoms, study says , , WEDNESDAY, Oct. 29 (HealthDay News) ... in people if they have other medical conditions, a new ... high cholesterol appeared to mask early MS symptoms and lead ... in the Oct. 29 online issue of Neurology . ...
Cached Medicine News:Health News:Cuts at General Motors Bring Benefit Trends to the Forefront 2Health News:Cuts at General Motors Bring Benefit Trends to the Forefront 3Health News:Jenny Craig Announces Finalists for the 2008 Ideal Size Contest 2Health News:WorldHeart Announces Effectiveness of Reverse Stock Split 2Health News:WorldHeart Announces Effectiveness of Reverse Stock Split 3Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 2Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 3Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 4Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 5Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 6Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 7Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 8Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 9Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 10Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 11Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 12Health News:Baby Quasar Lights Up Dillard's for the Retail Holiday Season 2Health News:Other Health Problems Can Delay MS Diagnosis 2
... Wristbands and Tags print in mere ... transfer printers. Direct thermal printers use ... coating under the bands protective surface. ... transfer highly durable ink from a ...
... in settings where a more secure band is ... easy to apply but difficult to remove wristband ... to suit the child. An additional label is ... wristband to ensure proper identification of the child. ...
IDENTI-MATCH II is a combination of the IDENTI-MATCH Blood Recipient Identification System and an admitting band. It has been designed for those facilities using label-based patient ID systems....
Integrate RFID and bar code technology with the new DR1000 Dual RFID/Bar Code Reader by Precision Dynamics Corporation (PDC). It provides an easy migration from bar codes to RFID tags for healthcare ...
Medicine Products: